PPARG and metabolic dysfunction-associated steatotic liver disease: PPARγ/SREBP-1c pathways are involved in alleviation of Antrodan-treated NAFLD via upregulated pAMPK and Sirt1, and downregulated PPARγ and SREBP-1c, thereby suppressing lipid biosynthesis and facilitating insulin resistance [31].